Navigation Links
Genomma Lab International Announces Second Quarter 2009 Results

MEXICO CITY, July 23 /PRNewswire/ -- Genomma Lab International, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended June 30, 2009. All figures included herein were prepared in accordance with Mexican GAAP; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican GAAP.

2Q09 Highlights (vs. 2Q08)

  • Net Sales reached Ps. 985.5 million, an increase of 50.7%.
  • Gross Profit was Ps. 724.8 million, an increase of 46.1%.
  • EBITDA(1) reached Ps. 256.9 million, an increase of 36.5%.
  • Consolidated Net Income of Ps. 122.9 million, an increase of 3.3%.
  • Earnings per Share(2) increased 16.8% to Ps. 1.03.
  • International Net Sales rose to Ps. 130.1 million, an increase of 220.9%.
  • During the second quarter, Genomma Lab successfully launched three products under three existing brands (Base Brands(3) and Prior Year Launches(4)) as part of the line extension strategy.
  • The Company also launched, during the second quarter, six products under six New Brands(5) as part of its new product launch plan.
  • As of June 30, 2009 the Company had a net cash position of Ps. 1,214.4 million.
  • During the second quarter of 2009, the Company acquired the brand of lotions Flor de Naranja Sanborns(MR), the brand of creams Teatrical, the brand of hair coloring Henna Egipcia, and a 99 year license for the use of Sanborns(MR) brands for the acquired brands.
  • Additionally, during the second quarter, the Company acquired the Jockey Club brand of men's personal care products. All of these brands are well-recognized brands in their respective markets and have been very popular among Mexican consumers for several decades.

(1) EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income.

(2) Earnings per share are for the last 12 months and were calculated using the weighted average number of shares outstanding for the period.

(3) As defined later in the document.

(4) As defined later in the document.

(5) As defined later in the document.

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman of the Board and Chief Executive Officer, stated: "We are pleased to report our second quarter 2009 results, which showed a sound growth. We are currently experiencing a challenging economic environment, which has made difficult the Global Economy's performance; therefore, we will continue to proceed with caution. We were, once again, pleasantly surprised by the net sales level registered during this quarter; which proves that both the Company's business model, as well as its advertising strategies, continue to be successful. We expect to continue in this manner so as to continue gaining market share, increasing net sales and profitability, and thus, creating value for our shareholders.

During the second quarter of 2009, we acquired several brands, some of them are expected to strengthen our presence in certain categories, whereas others will allow us to enter new categories. We continue analyzing new initiatives, and remain committed to the growth-by-acquisitions strategy established in our Initial Public Offering. We believe that adverse economic conditions can contribute to finding attractive expansion opportunities for the Company."

For the complete version of this earnings report, please visit:

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model, the Company had net sales of Ps. 2,629.4 million and EBITDA of Ps. 691.1 million in 2008.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B"


Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
2. Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns
3. Genomma Lab Internacional Announces First Quarter 2009 Results
4. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
5. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
6. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
7. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
8. Genomma Lab, New Participant in Market-Maker Program
9. Genomma Lab Announces Initiation of Stock Repurchase Fund
10. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
11. Genomma Lab Announces 2009 Earnings Guidance
Post Your Comments:
(Date:12/1/2015)... ... , ... Integrated Rental Services (“Integrated Rental”), a growing medical ... , With support from JII, Integrated Rental is poised for expansion while improving ... research labs and medical facilities across the United States. , General Manager Robert ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Califia ... today announced that its iconic bottle has won top honors in Beverage World Magazine’s ... The Company also announced that it has been selected as a 2015 U.S.A. Taste ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... we have seen vast improvements in scientific research and discoveries, leading us to ... increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that it has reached its enrollment ... Phase 3 clinical trial of aldoxorubicin in patients with ... to be completed in Q1 2016. The Phase 3 trial ... Special Protocol Assessment from the FDA at 79 sites ...
Breaking Medicine Technology: